THE NEED FOR EVEN FASTER ACTING INSULINS TO IMPROVE PATIENT OUTCOMES
Three new Ultra Rapid acting insulins that approximate the physiological profile of endogenously released insulin in the systemic circulation following a meal, are now available. They are: Afrezza®, Fiasp® and Lyumjev™ Can newer, even faster acting insulins be next? Do Ultra Rapid acting insulins offer advantages over current rapid acting mealtime insulins and is there a need for even faster insulins?
The purpose of THE NEED FOR EVEN FASTER ACTING INSULINS TO IMPROVE PATIENT OUTCOMES symposium is to answer:
1) Is Ultra Rapid insulin the ideal insulin for mealtime dosing?
2) Is Ultra Rapid insulin the ideal insulin for an insulin pump?
3) Is Ultra Rapid insulin the ideal insulin for an automated insulin delivery system?
4) Is there a need for even faster insulins?
Diabetes Technology Society invites healthcare professionals to hear a discussion by an endocrinologist, a diabetes care and education specialist, and a software developer for automated insulin delivery (closed loop) systems about recent advances in the use of Ultra Rapid insulin and current efforts in developing even faster acting insulin products to improve patient outcomes.
Date: Tuesday, March 2, 2021
Time: 9:00 - 10:30 AM Pacific / 12:00 - 1:30 PM Eastern / 6:00-7:30 PM Central European
Supported by a grant from Arecor
How to Register: https://us02web.zoom.us/webinar/register/WN_5Jrexo9kTeC-pII3Pt15AA